Anticancer Drugs Oncology Pharmacology Physiotherapy Ramucirumab

Ramucirumab (12)

In this article, we will discuss Ramucirumab (12). So, let’s get started.

Warnings (1)

Ramucirumab increased the risk of hemorrhage and gastrointestinal hemorrhage, including severe and sometimes fatal hemorrhagic events. In Study 1, the incidence of severe bleeding was 3.4% for Ramucirumab and 2.6% for placebo. In Study 2, the incidence of severe bleeding was 4.3% for Ramucirumab plus paclitaxel and 2.4% for placebo plus paclitaxel. Patients with gastric cancer receiving non steroid anti-inflammatory drugs (NSAIDs) were excluded from enrollment in Studies 1 and 2; therefore, the risk of gastric hemorrhage in Ramucirumab-treated patients with gastric tumors receiving NSAIDs is unknown. Permanently discontinue Ramucirumab in patients who experience severe bleeding.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.